Day: March 23, 2022

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, A solution of compound 9 (200mg, 0.39mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (212mg, 0.78mmol), and potassium hexafluorophosphate (108mg, 0.585mmol) in dry 1,2-dichloroethane (20mL) was stirred at 40°C for 24h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 10 as a dark red solid (198mg, 50percent). 1H NMR (300MHz, CDCl3): delta 8.88 (s, 1H), 8.83 (s, 1H), 8.75 (s, 2H), 8.27 (d, J=6Hz, 1H), 8.02 (dd, J=1.5Hz, 1.5Hz, 1H), 7.80 (d, J=5.4Hz, 1H), 7.84 (d, J=6.3Hz, 1H), 7.76(dd, J=1.5Hz, 1.5Hz, 1H), 7.69 (dd, J=1.5Hz, 1.5Hz, 1H), 7.59?7.64 (m, 5H), 7.30(d, J=5.4Hz, 1H), 7.01?7.16 (m, 1H), 6.89 (q, J=5.4Hz, 1H), 6.52 (q, J=7.8Hz, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.98 (s, 3H), 3.96 (s, 3H); 13C NMR (125MHz, CDCl3): delta 181.4, 164.3, 164.3, 164.1, 163.9, 162.1, 159.5 (d, JCF=252.1Hz), 157.9, 157.3, 156.6, 156.4, 155.4, 151.6, 150.7, 150.4, 145.6, 138.4, 137.2, 136.3, 135.8, 135.7, 135.4, 135.2, 128.1, 126.2, 126.1, 125.8, 125.7, 125.1, 122.8, 122.7, 122.1, 121.9, 121.6, 120.0, 119.0, 109.5 (d, JCF=22.7Hz), 53.4, 53.3, 53.2; HRMS (FAB): calcd. for C41H31FN5O8SRu [M+] 874.0921, found 874.0923.

71071-46-0 Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate 326419, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

71071-46-0, General procedure: A solution of compound 5 (400mg, 0.822mmol), [(eta6-p-cymene) RuCl2]2 (252mg, 0.411mmol), and Me4NCl (450mg, 4.11mmol) in anhydrous acetone (21mL) was stirred under a dark atmosphere at room temperature for 6h. The reaction mixture was filtered and the filtrate was evaporated to afford crude compound as a bright orange solid. The above intermediate (200mg, 0.373mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (203mg, 0.746mmol), and potassium hexafluorophosphate (103mg, 0.56mmol) were dissolved in dry 1,2-dichloroethane (20mL) and the mixture was stirred at 60°C for 12h. The mixture was then concentrated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 6 as a dark red solid (233mg, 70percent). 1H NMR (300MHz, CDCl3): delta 8.89 (s, 1H), 8.85 (s, 1H), 8.79 (s, 1H), 8.74 (s, 1H), 8.39 (d, J=5.7Hz, 1H), 8.00?7.91 (m, 3H), 7.82 (m, 3H), 7.67 (dd, J=3.6Hz, 1.5Hz, 1H), 7.52 (dt, J=8.7Hz, 1.2Hz, 1H), 7.46 (d, J=7.5Hz, 1H), 7.32?7.19 (m, 5H), 7.13 (d, J=5.7Hz, 1H), 6.72 (dt, J=6.5Hz, 1.5Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 1.27 (s, 3H); 13C NMR (125MHz, CDCl3): delta 192.8, 164.6, 164.4, 164.2, 162.6, 157.9, 157.8, 156.5, 156.3, 155.6, 151.9, 151.4, 150.5, 149.8, 142.5, 142.4, 138.4, 137.3, 136.6, 135.6, 135.3, 135.0, 134.9, 129.4, 128.5, 127.9, 127.6, 126.3, 162.2, 125.8, 123.0, 122.9, 122.4, 120.4, 118.8, 53.6, 53.5, 53.4, 53.3, 15.5; HRMS (FAB):calcd. for C44H36N5O8RuS [M+] 896.1328, found 896.1321.

As the paragraph descriping shows that 71071-46-0 is playing an increasingly important role.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.118949-61-4,2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%.

118949-61-4, As the paragraph descriping shows that 118949-61-4 is playing an increasingly important role.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1148-79-4, 2,2′:6′,2”-Terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

UO2Cl2(terpy) (3): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine, 2.3 ml (19 mmol) acetonitrile and 1.1 ml (12 mmol) pyridine was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 79percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3)., 1148-79-4

As the paragraph descriping shows that 1148-79-4 is playing an increasingly important role.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

27318-90-7, 1,10-Phenanthroline-5,6-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A solution containing 1,10-phenanthroline-5,6-dione (1.6 mmol, 347 mg), substituted benzaldehyde (1.6 mmol), 20 ml of HAc and NH4Ac (33 mmol, 2.53 g), was heated at 110 °C under reflux for 4 h. Then, 20 ml of water was added and the pH value was adjusted to 7.0 at room temperature. The solution was filtered and dried in vacuum to obtain a yellow precipitate. The product was purified in a silica gel column by using ethanol as eluent. 1a: yield 78.4percent; mp. 217-219 °C, ESI-MS (in MeOH): m/z: 219.1, ([M + H]), 438.1,([M + 2H]2+). 2a: yield 79.5percent; mp. 226-228 °C, ESI-MS (in MeOH): m/z: 339.15, ([M + H]+), 678.1, ([M + 2H]2+). 3a: yield 64.4percent; mp. 262-265 °C, ESI-MS (in MeOH): m/z: 325.1, ([M + H]+), 650.3, ([M + 2H]2+). 4a: yield 75.7percent; mp. 234-236 °C, ESI-MS (in MeOH): m/z: 311.1, ([M + H]+). 5a: yield 67.1percent; mp. 232-235 °C, ESI-MS (in MeOH): m/z: 339.1, ([M + H]+). 6a: yield 67.7percent; mp. 280-283 °C, ESI-MS (in MeOH): m/z: 363.1, ([M + H]+), 726.1, ([M + 2H]2+). 7a: yield 63.4percent; mp. 269-273 °C, ESI-MS (in MeOH): m/z: 375.2, ([M + H]+), 750, ([M 2H]2+), 772.8, ([M + H + Na]2+).

27318-90-7, 27318-90-7 1,10-Phenanthroline-5,6-dione 72810, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Wu, Qiong; Fan, Cundong; Chen, Tianfeng; Liu, Chaoran; Mei, Wenjie; Chen, Sidong; Wang, Baoguo; Chen, Yunyun; Zheng, Wenjie; European Journal of Medicinal Chemistry; vol. 63; (2013); p. 57 – 63;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%.

118949-61-4, The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, General procedure: A solution of cis-RuII(bpz)2Cl2 (100 mg, 0.205 mmol) and AgNO3 (77 mg, 0.453 mol) in water (25 mL) was heated at reflux for 48 h. After cooling to room temperature, the mixture was filtered through Celite to remove AgCl, and the filtrate was evaporated to dryness. The residue was dissolved in DMF (15 mL) and the solution purged with argon for 15 min. 4,4?-bis(trifluoromethyl)-2,2?-bipyridyl (121 mg, 0.414 mmol) was added and the mixture heated at 100 °C for 24 h under argon. After cooling to room temperature, the solution was evaporated under vacuum to a small volume and diethyl ether (150 mL) added. The precipitate was filtered off and dissolved in a minimum of cold water to which solid NH4PF6 was added. The solid was filtered off and purified by column chromatography as for 1 to give an orange solid. Yield: 73 mg (35percent).

The synthetic route of 71071-46-0 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Coe, Benjamin J.; Peers, Martyn K.; Scrutton, Nigel S.; Polyhedron; vol. 96; (2015); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

22348-32-9, (R)-Diphenyl(pyrrolidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3A. Preparation of TMS-prolinolTo a mixture of prolinol (10.0 g, 39.5 mmol) and imidazole (4.57 g, 67.1 mmol) in THF (100 mL) was added chlorotrimethylsilane (5.57 g, 51.3 mmol) over 15 min while maintaining the batch temperature below 30 0C. The resulting slurry was aged at 50 0C for 3-5 h. The reaction mixture was cooled to ambient tempearture and quenched by addition of MTBE (50 mL) and 15% aq NaCl (100 mL). The organic layer was washed with 15% aq NaCl (50 mL). The solution was azeotropically dried at the constant volume by feeding THF.HPLC MethodColumn: Ascentis Express Cl 8 (100×4.6mm, 2.7um)Column temperature: 45 0CFlow rate: 1.5 ml/minDetection: UV at 210nmGradient:Time(min) 0.1% H^PO4 (0A) MeCN (0A)0 95 51 95 512 10 90Retention times (minutes): prolinol (4.8 min); TMS prolinol (7.3 min), 22348-32-9

The synthetic route of 22348-32-9 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; MERCK SHARP &; DOHME CORP.; XU, Feng; DESMOND, Richard; HOERRNER, R. Scott; HUMPHREY, Guy, R.; ITOH, Tetsuji; JOURNET, Michel; YOSHIKAWA, Naoki; ZACUTO, Michael, J.; WO2010/144293; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI